Fruquintinib, sintilimab, and chemo for stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs (fruquintinib, sintilimab, and CAPEOX chemotherapy) as a first treatment for advanced stomach or gastroesophageal cancer. The goal is to see if this combination helps slow or shrink the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced stomach or gastroesophageal junction cancer that hasn't been treated yet, and it is HER2-negative or your HER2 status is not known.
- You are between 18 and 75 years old and are in generally good health (able to do daily activities).
- You have not had previous treatments that target VEGF (like bevacizumab) or PD-1/PD-L1 (like pembrolizumab).
- You have at least one tumor that can be measured on a scan.
- Your blood counts, liver, kidney, and heart function are within safe limits.
- You are willing to use effective birth control during and for a time after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs (fruquintinib, trastuzumab, and XELOX chemotherapy) as the first treatment for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The goal is to see if this combination is safe and effective for shrinking tumors.
This trial tests adding fruquintinib (a targeted drug that blocks blood vessel growth) to chemotherapy after surgery for HER2-negative stomach or gastroesophageal junction cancer. It is for patients whose tumor did not respond well to previous treatment before surgery.
This trial tests a combination of two targeted drugs (fruquintinib and sintilimab) plus standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of an oral targeted therapy (fruquintinib), an immunotherapy (PD-1 inhibitor), and chemotherapy (FOLFOX) as the first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this triplet therapy helps control the cancer better than standard treatments.
This trial tests a combination of fruquintinib (a pill that blocks blood vessel growth), sintilimab (an immunotherapy), and targeted radiation for people with stomach or GEJ cancer that has only a few new spots after at least one prior treatment. The goal is to see if this triple approach helps control the cancer better than standard options.
This trial tests a combination of immunotherapy (PD-1 inhibitor), a targeted drug (fruquintinib), and chemotherapy as a first treatment for advanced stomach or gastroesophageal junction cancer that is HER2-negative. It aims to see if this combination can shrink tumors and help people live longer.
Hear when a new Metastatic Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.